Senior / Principal Scientist, Translational Sciences

Senior / Principal Scientist, Translational Sciences Job summary :

• PharmaEssentia Innovation Research Center (PIRC) is seeking a highly motivated and experienced senior or principal scientist to join our Translational Sciences team and contribute to the development of first-in-class and best-in-class biotherapeutics, including cytokines, antibodies, and antibody-drug-conjugates.
• The successful candidate will contribute to the design, execution, and interpretation of translational biomarker and mechanism of action (MOA) studies to support the development and regulatory approval of novel therapeutics as they transition from late discovery into first in human clinical trials and beyond.
• In this position, you will utilize your expertise in pharmacokinetics, pharmacodynamics, and biomarker discovery to guide drug development and biomarker strategies, optimize dosing regimens, and ensure the safety and efficacy of investigational drugs.
• You will also contribute to translational activities aimed at maximizing the potential of BESREMI, PharmaEssentia’s marketed drug for the treatment of myeloproliferative neoplasms.
• These efforts include indication expansion, novel combinations, and refining / improving biomarker approaches to guide dosing and patient selection.
• Additionally, you will provide scientific leadership, mentorship, and cross-functional collaboration within the Translational Sciences team and across other departments.

The Company :

Founded in 2003 by a team of Taiwanese American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today we are listed on the Taipei Exchange (TPEx :

Summary of Key Responsibilities :

Further Exploration of BESREMi :

Data Analysis and Interpretation :

Drug Development Strategy :

Regulatory Interaction :

Scientific Leadership :

Cross-Functional Collaboration :

Qualifications :

Conclusion :

By joining our team, you will not only expand your own possibilities, but you will contribute to expanding options for people with cancer. https :